Начало › Рак на белия дроб с недребноклетъчен тип › Вашингтон › Seattle
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Seattle, WA
53 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Seattle (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Набиране на участнициФаза 2/3
- Fred Hutchinson Cancer Center. /ID# 277939, Seattle
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Набиране на участнициФаза 3
- Swedish Cancer Institute ( Site 0143), Seattle
- St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale · на 17 мили
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Swedish Medical Center-First Hill, Seattle
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Набиране на участнициФаза 3
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Swedish Cancer Institute, Seattle
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Набиране на участнициНаблюдателно проучване
- Fred Hutchinson Cancer Center, Seattle
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Набиране на участнициФаза 2
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Swedish Medical Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Swedish Medical Center, Seattle
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Research Site, Seattle
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Набиране на участнициФаза 3
- Local Institution - 0508, Seattle
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Набиране на участнициФаза 1/2
- University of Washington Fred Hutchinson Cancer Center, Seattle
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Набиране на участнициФаза 1
- University of Washington Fred Hutchinson, Seattle
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Research Site, Seattle
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Набиране на участнициФаза 2
- Fred Hutchison Cancer Center, Seattle
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, Seattle
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Набиране на участнициФаза 1/2
- Fred Hutchinson Cancer Research Center, Seattle
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Набиране на участнициФаза 2
- University of Washington (Data Collection Only), Seattle
A Study of KK2269 in Adult Participants With Solid Tumors
Набиране на участнициФаза 1
- University of Washington, Seattle
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
SMP-3124LP in Adults With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- University of Washington, Seattle
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
Набиране на участници
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- Fred Hutchinson Cancer Center, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- Swedish Cancer Institute, Seattle
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Набиране на участнициФаза 1
- University Of Washington, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Набиране на участнициФаза 1
- Swedish Cancer Institute, Seattle
- Swedish Medical Center, Seattle
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Набиране на участнициФаза 1/2
- Fred Hutchinson Cancer Research Center, Seattle
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 2
- Seattle Cancer Care Alliance, Seattle
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
Набиране на участници
- Fred Hutch/University of Washington Cancer Consortium, Seattle
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- Fred Hutchinson Cancer Center, Seattle
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- и още 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Набиране на участнициФаза 1/2
- Virginia Mason Medical Center, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Swedish Medical Center-First Hill, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Swedish Medical Center-First Hill, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Набиране на участнициФаза 1/2
- Virginia Mason Medical Center, Seattle
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 2
- Swedish Cancer Institute, Seattle
- Swedish Medical Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- Fred Hutch Cancer Center, Seattle
A Study of NX-1607 in Adults With Advanced Malignancies
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- Swedish Health Sciences, Seattle
- Research Site, Seattle
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Набиране на участнициФаза 2
- Fred Hutchinson Cancer Center, Seattle
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в Seattle
- Рак (всички видове)49 проучвания
- Рак на простатата42 проучвания
- Остра миелоидна левкемия41 проучвания
- Рак на гърдата39 проучвания
- Метастатичен рак39 проучвания
- Колоректален рак34 проучвания
- Рак на белия дроб33 проучвания
- Рак на яйчниците30 проучвания
- Множествен миелом22 проучвания
- Рак на пикочния мехур21 проучвания
- Миелодиспластични синдроми21 проучвания
- Остра лимфобластна левкемия21 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.